Basic information
- CAS
297-90-5- Standard SMILES
CN1CCC23CCCCC2C1Cc1ccc(O)cc13- InChIKey
JAQUASYNZVUNQP-UHFFFAOYSA-N- Molecular formula
- C17H23NO
- Average molar mass
- 257.37 g/mol
- Monoisotopic mass
- 257.17796436
Overview
Racemorphan is a DEA Schedule II controlled substance. Substances in the DEA Schedule II have a high potential for abuse which may lead to severe psychological or physical dependence. It is a Opiates substance.
Names & identifiers
- Preferred name
- Orphan
- IUPAC
- 17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol
Names & synonyms
RacemorphanRacemorfanoRacemorphaneIDS-NR-003NU-2206RacemorphanumAntalginNU 2206DTXSID301016136RefChem:1093908DTXCID301474275206-048-0
Show more names
297-90-5Cetarindl-3-Hydroxy-N-methylmorphinanDromoranMethorphinanN-Methyl-3-hydroxymorphinanOrphanRacemic dromoran
Database identifiers
- CAS
297-90-5- PubChem CID
- 3918
- ChEMBL
CHEMBL20803- EC Number
- 206-048-0
- Nikkaji
- J23.924K
Properties
Computed structural properties
- XLogP
- 3.1
- Topological polar surface area
- 23.5 Ų
- Hydrogen bond donors
- 1
- Hydrogen bond acceptors
- 2
- Rotatable bonds
- 0
- Heavy atoms
- 19
- Formal charge
- 0
- Complexity
- 357
Experimental & physicochemical properties
Drugs
DEA NFLIS-Drug Category -> Narcotic Analgesics
DEA Schedule II Controlled Substance -> Opiates
Safety & regulation
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Hazard information
Regulatory InformationDEA schedule II controlled substance
Toxicology
Treatment
The specific treatment of suspected levorphanol tartrate overdosage is immediate establishment of an adequate airway and ventilation, followed (if necessary) by intravenous naloxone. The respiratory and cardiac status of the patient should be continuously monitored and appropriate supportive measures instituted, such as oxygen, intravenous fluids and/or vasopressors, if required. Physicians are reminded that the duration of levorphanol action far exceeds the duration of action of naloxone, and repeated dosing with naloxone may be required. Naloxone should be administered cautiously to persons known or suspected to be physically dependent on Levorphanol. In such cases an abrupt and complete reversal of opioid effects may precipitate an acute abstinence syndrome. If necessary to administer naloxone to the physically dependent patient, the antagonist should be administered with extreme care and by titration with smaller than usual doses of the antagonist. (L1712)
Health EffectsMedical problems can include congested lungs, liver disease, tetanus, infection of the heart valves, skin abscesses, anemia and pneumonia. Death can occur from overdose.
Exposure RoutesSubcutaneous, Intravenous, or Intramuscular injection ; Oral. Levorphanol is well absorbed after PO administration with peak plasma concentrations occurring approximately 1 hour after dosing.
Toxicity SummaryLike other mu-agonist opioids it is believed to act at receptors in the periventricular and periaqueductal gray matter in both the brain and spinal cord to alter the transmission and perception of pain.
Signs and SymptomsSigns of overdose include nausea, emesis, dizziness, respiratory depression, hypotension, urinary retention, cardiac arrhythmias, allergic reactions, skin rash, and uticaria.
Chemistry & industry
Pharmacology
Metabolism/MetabolitesLevorphanol is extensively metabolized in the liver and is eliminated as the glucuronide metabolite.
Half Life: 11-16 hours
Uses & manufacturing
UsesFor the management of moderate to severe pain or as a preoperative medication where an opioid analgesic is appropriate
Related reactions
0 records
No reaction records under the current filter.
Compound notes
Loading…